Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
16 studies found for:    "methodist hospital" | Open Studies | "Intestinal Diseases" | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
Conditions: Human Papillomavirus-Related Carcinoma;   Human Papillomavirus Positive Oropharyngeal Carcinoma;   Human Papillomavirus Positive Cervical Carcinoma;   Human Papillomavirus Positive Anal Carcinoma;   Human Papillomavirus Positive Vulvar Carcinoma;   Human Papillomavirus Positive Penile Carcinoma
Interventions: Biological: HPV Specific T Cells;   Drug: Cytoxan;   Drug: Fludarabine;   Biological: Nivolumab
2 Recruiting TAA-Specific CTLS for Solid Tumors (TACTASOM)
Conditions: Bladder Cancer;   Breast Cancer;   Colorectal Cancer;   Endometrial Cancer;   Gastric Cancer;   Head and Neck Cancer;   HCC;   Lung Cancer;   Melanoma;   Neuroblastoma;   Sarcoma (Osteo-, Synovial, Rhabdomyo-, Etc);   Pancreatic Cancer;   Prostate Cancer;   Renal Cell Carcinoma;   Thyroid Cancer
Intervention: Biological: TAA-Specific CTLs
3 Recruiting A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Conditions: Colitis, Ulcerative;   Inflammatory Bowel Diseases
Interventions: Drug: Placebo IV;   Drug: Placebo SC;   Drug: Ustekinumab IV;   Drug: Ustekinumab SC
4 Recruiting Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Apremilast;   Drug: Placebo
5 Recruiting A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Condition: Ulcerative Colitis
Intervention:
6 Recruiting Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: GED-0301;   Drug: Placebo
7 Not yet recruiting A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: GED-0301;   Drug: Placebo
8 Recruiting Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: JNJ-64304500;   Drug: Placebo;   Drug: Ustekinumab
9 Recruiting Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
Condition: Crohn Disease
Intervention: Drug: etrolizumab
10 Recruiting A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: Etrolizumab 210 mg;   Drug: Etrolizumab 105 mg;   Drug: Placebo
11 Recruiting PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Condition: Colorectal Cancer
Interventions: Drug: FOLFOX (chemotherapy);   Other: 5 FUCMT (chemoradiation);   Procedure: surgery;   Procedure: magnetic resonance imaging or endorectal ultrasound
12 Recruiting S0820, Adenoma and Second Primary Prevention Trial
Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
13 Recruiting Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: RPC1063
14 Recruiting Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: RPC1063;   Drug: Placebo
15 Recruiting A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome
Condition: Short Bowel Syndrome
Intervention:
16 Recruiting A Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection
Conditions: Rectal Cancer;   Rectosigmoid Cancer
Interventions: Device: PINPOINT;   Device: SPY Elite

Study has passed its completion date and status has not been verified in more than two years.